fluconazole has been researched along with Obesity, Morbid in 4 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because morbid obesity may confer a relative immunodeficiency, morbidly obese patients may develop unusual infections such as opportunistic fungal abscesses." | 1.42 | Tubo-Ovarian Abscess Caused by Candida Albicans in an Obese Patient. ( Gurberg, J; Krishnamurthy, S; To, V, 2015) |
| " Pharmacokinetic parameters calculated were maximum serum concentration 9." | 1.40 | Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration. ( Lopez, ND; Phillips, KM, 2014) |
| "In the absence of clinical studies, the ability to project the direction and the magnitude of changes in bioavailability of drug therapy, using evidence-based mechanistic pharmacokinetic in silico models would be of significant value in guiding prescribers to make the necessary adjustments to dosage regimens for an increasing population of patients who are undergoing bariatric surgery." | 1.38 | A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. ( Ammori, BJ; Ashcroft, DM; Darwich, AS; Jamei, M; Pade, D; Rostami-Hodjegan, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rebibo, L | 1 |
| Dupont, H | 1 |
| Levrard, M | 1 |
| Cosse, C | 1 |
| Dhahri, A | 1 |
| Verhaeghe, P | 1 |
| Regimbeau, JM | 1 |
| Lopez, ND | 1 |
| Phillips, KM | 1 |
| To, V | 1 |
| Gurberg, J | 1 |
| Krishnamurthy, S | 1 |
| Darwich, AS | 1 |
| Pade, D | 1 |
| Ammori, BJ | 1 |
| Jamei, M | 1 |
| Ashcroft, DM | 1 |
| Rostami-Hodjegan, A | 1 |
4 other studies available for fluconazole and Obesity, Morbid
| Article | Year |
|---|---|
Letter to editor: "Gastric fistula after laparoscopic sleeve gastrectomy: don't forget to treat for Candida".
Topics: Adult; Antifungal Agents; Ascitic Fluid; Candida; Candidiasis; Female; Fluconazole; Gastrectomy; Gas | 2013 |
Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration.
Topics: Antifungal Agents; Area Under Curve; Critical Illness; Drug Monitoring; Fluconazole; Half-Life; Hemo | 2014 |
Tubo-Ovarian Abscess Caused by Candida Albicans in an Obese Patient.
Topics: Abscess; Adult; Anti-Bacterial Agents; Antifungal Agents; Candida albicans; Candidiasis; Drainage; D | 2015 |
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
Topics: Administration, Oral; Bariatric Surgery; Biological Availability; Chemistry, Pharmaceutical; Ciprofl | 2012 |